Lee Y C, Lane K B, Parker R E, Ayo D S, Rogers J T, Diters R W, Thompson P J, Light R W
Department of Pulmonary Medicine, St Thomas Hospital, Nashville, Tennessee 37202, USA.
Thorax. 2000 Dec;55(12):1058-62. doi: 10.1136/thorax.55.12.1058.
We have recently shown that transforming growth factor (TGF)beta(2) induces effective pleurodesis in rabbits. However, rabbits have a thin pleura while humans have a thick visceral pleura. The effect of intrapleural administration of TGF beta(2) in animals with a thick pleura and its associated systemic effects have not been investigated. This study was undertaken (1) to develop a new animal model for the study of pleurodesis using sheep which have a thick pleura resembling that of humans; (2) to study the efficacy of TGF beta(2) as a pleurodesis agent in the sheep model; and (3) to assess whether histological changes occur in extrapulmonary organs after intrapleural administration of TGF beta(2).
Twelve sheep were divided into four groups and were given a single intrapleural injection of TGF beta(2) in a concentration of 1.0 microg/kg, 0.5 microg/kg, 0.25 microg/kg or 0.125 microg/kg to the right pleural cavity via a chest tube. The left pleural cavity served as the control. Any pleural fluid that accumulated after the intrapleural TGF beta(2) injection was collected and analysed. The degree of pleurodesis was graded from 1 (no adhesions) to 8 (complete symphysis >50% of chest wall) at day 14 when the sheep were killed. Biopsy specimens were taken from the lungs and extrapulmonary organs.
All sheep that received > or = 0.25 microg/kg TGF beta(2) developed excellent pleurodesis (score = 8) while those that received 0.125 microg/kg had a median score of 6. The pleurodesis score did not exceed 2 in the control (left) side of any sheep. Sheep receiving > or = 0.50 microg/kg TGF beta(2) developed large exudative pleural effusions while those receiving a lower dose did not. The production of effusions neither hindered nor was necessary for inducing pleurodesis. There were no significant fibrotic changes in any of the extrapulmonary organs.
Intrapleural injection of 0.25-1.0 microg/kg TGF beta(2) produces excellent pleurodesis in a new sheep model with no evidence of extrapulmonary fibrosis.
我们最近发现转化生长因子(TGF)β2可在兔身上诱导有效的胸膜固定术。然而,兔的胸膜较薄,而人的脏层胸膜较厚。胸膜内注射TGFβ2在胸膜较厚的动物中的效果及其相关的全身影响尚未得到研究。本研究旨在:(1)建立一种新的动物模型,使用胸膜较厚类似于人类的绵羊来研究胸膜固定术;(2)研究TGFβ2作为胸膜固定剂在绵羊模型中的疗效;(3)评估胸膜内注射TGFβ2后肺外器官是否发生组织学变化。
将12只绵羊分为四组,通过胸管向右侧胸腔单次胸膜内注射浓度为1.0μg/kg、0.5μg/kg、0.25μg/kg或0.125μg/kg的TGFβ2。左侧胸腔作为对照。胸膜内注射TGFβ2后积聚的任何胸腔积液均收集并分析。在第14天处死绵羊时,将胸膜固定程度从1级(无粘连)分级至8级(完全愈合>胸壁的50%)。从肺和肺外器官获取活检标本。
所有接受≥0.25μg/kg TGFβ2的绵羊均产生了良好的胸膜固定(评分=8),而接受0.125μg/kg的绵羊中位评分为6。任何绵羊对照(左)侧的胸膜固定评分均未超过2。接受≥0.50μg/kg TGFβ2的绵羊出现大量渗出性胸腔积液,而接受较低剂量的绵羊则未出现。积液的产生既不阻碍也不是诱导胸膜固定所必需的。任何肺外器官均未出现明显的纤维化改变。
在新的绵羊模型中,胸膜内注射0.25 - 1.0μg/kg TGFβ2可产生良好的胸膜固定,且无肺外纤维化的证据。